Table 8. Prescribed pharmacological treatments for heart failure over time.
| At discharge | At 12 months | |||||
| Rate of use | Dose (mg/day) | ≥ 50% of target dose | Rate of use | Dose (mg/day) | ≥ 50% of target dose | |
| ACEIs/ARBs | 62.1% | 24.4% | 57.7% | 24.3% | ||
| ACEIs | 27.5% | 27.1% | 16.9% | 36.2% | ||
| Ramipril | 33.8% | 4.5 ± 4.2 | 34.6% | 44.2% | 4.6 ± 4.4 | 36.1% |
| Captopril | 30.3% | 29.0 ± 22.9 | 14.8% | 15.3% | 31.1 ± 20.8 | 12.0% |
| Enalapril | 23.6% | 8.1 ± 8.9 | 31.6% | 20.2% | 12.3 ± 11.9 | 54.5% |
| ARBs | 34.6% | 22.3% | 40.8% | 20.0% | ||
| Candesartan | 39.7% | 7.2 ± 5.0 | 14.4% | 32.9% | 6.8 ± 5.2 | 10.0% |
| Valsartan | 35.0% | 114.1 ± 62.0 | 39.0% | 40.3% | 112.4 ± 61.8 | 34.4% |
| Losartan | 16.4% | 41.4 ± 29.1 | 6.0% | 16.5% | 40.5 ± 18.8 | 4.6% |
| Beta-blockers | 59.6% | 20.6% | 66.2% | 26.3% | ||
| Bisoprolol | 57.9% | 2.5 ± 2.0 | 21.7% | 62.0% | 2.7 ± 1.9 | 27.4% |
| Carvedilol | 37.5% | 13.6 ± 14.1 | 20.7% | 33.7% | 15.0 ± 13.5 | 25.3% |
| Metoprolol | 1.3% | 40.0 ± 26.2 | 18.2% | 2.8% | 48.6 ± 36.1 | 27.8% |
| MRAs | 49.0% | 86.2% | 40.8% | 86.6% | ||
| Spironolactone | 98.7% | 28.9 ± 14.2 | 86.0% | 99.5% | 32.8 ± 29.3 | 86.6% |
| Eplerenone | 1.3% | 52.8 ± 19.5 | 100% | 0.5% | 75.0 ± 35.4 | 100% |
| Diuretics | 82.2% | 75.9% | ||||
| Digitalis | 25.9% | 24.0% | ||||
| Nitrate | 36.4% | 32.2% | ||||
| Hydralazine | 4.9% | 4.2% |
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.